Abstract:Calcium/calmodulin‐dependent protein kinase kinase 2 (CaMKK2) and mitochondrial sodium/calcium exchanger protein (NCLX) are key regulatory factors in calcium homeostasis. Finding natural drugs that target regulators of calcium homeostasis is critical. Dihydroartemisinin (DHA) is considered to have anticancer effects. The present study aimed to investigate the mechanism of DHA in regulating liver cancer migration and invasion. The present study used HepG2 and HuH‐7 cells and overexpressed CaMKK2 and knocked down CaMKK2 and NCLX. The antiproliferative activity of DHA on liver cancer cells was assessed through colony formation and EdU assays. Cell apoptosis was detected through YO‐PRO‐1/PI staining. The levels of reactive oxygen species (ROS) were measured using a ROS detection kit (DCFH‐DA fluorescent probe). Cell migratory and invasive abilities were examined using wound healing and Transwell assays. The ATP production of liver cancer cells was detected using ATP fluorescent probes. Cell microfilaments were monitored for changes using Actin‐Tracker Green‐488. The effects of DHA on the expression of CaMKK2, NCLX, sodium/potassium‐transporting ATPase subunit α‐1 (ATP1A1) and ATP synthase subunit d, mitochondrial (ATP5H) were determined by western blotting and reverse transcription‐quantitative PCR. The results revealed that DHA significantly inhibited proliferation, reduced ROS levels and promoted apoptosis in liver cancer cells. CaMKK2 overexpression significantly enhanced the invasive and migratory ability of liver cancer cells, whereas DHA inhibited the pro‐migratory effects of CaMKK2 overexpression. DHA significantly reduced the mitochondrial ATP production and altered the arrangement of microfilaments in liver cancer cells. In addition, DHA significantly decreased the expression of CaMKK2, NCLX, ATP1A1 and ATP5H. Furthermore, by knockdown experiments of NCLX the results demonstrated that CaMKK2 downregulated the expression of ATP1A1 and ATP5H in liver cancer cells through NCLX. In conclusion, DHA may reduce ATP synthase production via the CaMKK2/NCLX signaling pathway to inhibit the invasive phenotype of liver cancer cells. It is essential to further investigate the effectiveness of DHA in the anticancer mechanism of liver cancer cells.

Anti-malarial Drug Dihydroartemisinin Downregulates the Expression Levels of CDK1 and CCNB1 in Liver Cancer

Dihydroartemisinin inhibits liver cancer cell migration and invasion by reducing ATP synthase production through CaMKK2/NCLX

Dihydroartemisinin sensitizes Lewis lung carcinoma cells to carboplatin therapy via p38 mitogen-activated protein kinase activation.

Target prediction and potential application of dihydroartemisinin on hepatocarcinoma treatment

Dihydroartemisinin Induces Apoptosis of Cervical Cancer Cells Via Upregulation of RKIP and Downregulation of Bcl-2.

Dihydroartemisinin Suppresses Pancreatic Cancer Cells Via a Microrna-Mrna Regulatory Network

Dihydroartemisinin Exhibits Antitumor Activity Toward Hepatocellular Carcinoma in Vitro and in Vivo.

Dihydroartemisinin promoted FXR expression independent of YAP1 in hepatocellular carcinoma

Dihydroartemisinin Inhibits the Proliferation of Esophageal Squamous Cell Carcinoma Partially by Targeting AKT1 and p70S6K

Dihydroartemisinin Inhibits EMT Induced by Platinum-Based Drugs Via Akt-Snail Pathway

Dependence of Artesunate on Long Noncoding RNA‐RP11 to Inhibit Epithelial‐mesenchymal Transition of Hepatocellular Carcinoma

Dihydroartemisinin inhibited stem cell-like properties and enhanced oxaliplatin sensitivity of colorectal cancer via AKT/mTOR signaling.

Dihydroartemisinin remodels tumor micro-environment and improves cancer immunotherapy through inhibiting cyclin-dependent kinases

Dihydroartemisinin inhibits HepG2.2.15 proliferation by inducing cellular senescence and autophagy

Dihydroartemisinin reduced lipid droplet deposition by YAP1 to promote the anti-PD-1 effect in hepatocellular carcinoma

Dihydroartemisinin inhibits the development of colorectal cancer by GSK-3β/TCF7/MMP9 pathway and synergies with capecitabine

Dihydroartemisinin inhibited the Warburg effect through YAP1/SLC2A1 pathway in hepatocellular carcinoma

Histone Deacetylase Inhibitors Facilitate Dihydroartemisinin-Induced Apoptosis In Liver Cancer In Vitro And In Vivo

Dihydroartemisinin inhibits ATP6 activity, reduces energy metabolism of hepatocellular carcinoma cells, promotes apoptosis and inhibits metastasis via CANX

Effects of Dihydroartemisinin, a Metabolite of Artemisinin, on Colon Cancer Chemoprevention and Adaptive Immune Regulation

Dihydroartemisinin-driven selective anti-lung cancer proliferation by binding to EGFR and inhibition of NRAS signaling pathway-induced DNA damage